噬血细胞性淋巴组织细胞增多症
多器官衰竭
地塞米松
医学
鲁索利替尼
免疫学
爱泼斯坦-巴尔病毒
病毒
病毒学
内科学
骨髓
骨髓纤维化
疾病
作者
Juan Liang,Xiaojun Xu,Zhenjie Chen,Yu Jiao,Yongmin Tang
出处
期刊:Journal of Pediatric Hematology Oncology
[Ovid Technologies (Wolters Kluwer)]
日期:2024-04-26
被引量:1
标识
DOI:10.1097/mph.0000000000002856
摘要
Anti–interferon-γ monoclonal antibody emapalumab and JAK1/2 inhibitors ruxolitinib have been widely reported for the treatment of hemophagocytic lymphohistiocytosis (HLH) recently. These targeted drugs have fewer side effects and may provide new options for patients with HLH who are refractory to previous treatment or intolerant to chemotherapy. Herein, we reported a case of Epstein-Barr virus–related HLH, which did not respond well to HLH-94 plus ruxolitinib and developed severe fungal infection. The disease was successfully controlled after a combination therapy of emapalumab, ruxolitinib, and dexamethasone.
科研通智能强力驱动
Strongly Powered by AbleSci AI